[ Xeris Pharmaceuticals raises $30M in Series D funding ]
Xeris Pharmaceuticals has raised $30 million in Series D funding.
Founded in 2005, Xeris Pharmaceuticals specialty biopharmaceutical company developing improved and differentiated injectable therapeutics for multiple indications including diabetes. The company’s proprietary XeriSol(TM) and XeriJect(TM) formulation technologies allow for the subcutaneous and intradermal delivery of highly concentrated, non-aqueous, ready-to-inject formulations of peptides, proteins, antibodies and small molecules using auto-injectors, multi-dose pens and pumps.
With the new funds, the company expects to fund registration trials and the commercial launch of Xeris’ lead product, G-Pen(TM) a novel glucagon injection for treatment of severe hypoglycemia, as well as clinical validation of novel products leveraging Xeris’ unique formulation platform.
|Founder / CEO||Paul R. Edick|
|Previous Investors||Redmile Group|
|Central Texas Angel Network|
|Texas Venture Labs|